MCID: SCH003
MIFTS: 40

Schizophreniform Disorder malady

Categories: Mental diseases

Aliases & Classifications for Schizophreniform Disorder

Aliases & Descriptions for Schizophreniform Disorder:

Name: Schizophreniform Disorder 12 14
Schizophreniform Disorders 52 69
Psychotic Disorders 42 69

Classifications:



External Ids:

Disease Ontology 12 DOID:11328
ICD10 33 F20.81
ICD9CM 35 295.4
MeSH 42 D011618
NCIt 47 C94376
SNOMED-CT 64 88975006
UMLS 69 C0036358

Summaries for Schizophreniform Disorder

Disease Ontology : 12 A psychotic disorder that involves schizophrenia symptoms over time period of one month.

MalaCards based summary : Schizophreniform Disorder, also known as schizophreniform disorders, is related to schizophrenia and personality disorder, and has symptoms including fatigue, sleep disturbances and photophobia. An important gene associated with Schizophreniform Disorder is PRL (Prolactin), and among its related pathways/superpathways is Signaling by ERBB4. The drugs Dopamine and Sulpiride have been mentioned in the context of this disorder. Affiliated tissues include brain, thyroid and spinal cord.

Wikipedia : 71 Schizophreniform disorder is a mental disorder diagnosed when symptoms of schizophrenia are present for... more...

Related Diseases for Schizophreniform Disorder

Diseases related to Schizophreniform Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 52)
id Related Disease Score Top Affiliating Genes
1 schizophrenia 30.1 COMT DRD2 NRG1 PRL
2 personality disorder 29.3 COMT DRD2 NRG1
3 lung occult small cell carcinoma 10.2 DRD2 PRL
4 pfeiffer rockelein syndrome 10.2 DRD2 PRL
5 ornithosis 10.2 DRD2 PRL
6 pulmonary neuroendocrine tumor 10.1 DRD2 PRL
7 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovasuclar malformations 10.1 DRD2 PRL
8 nephrogenic adenoma of the urethra 10.1 DRD2 PRL
9 transmitted_by 10.1 DRD2 PRL
10 bile acid synthesis defect, congenital, 4 10.1 DRD2 PRL
11 cold-induced sweating syndrome 2 10.1 DRD2 PRL
12 mucinous adenocarcinoma 10.1 DRD2 PRL
13 alopecia 10.0 DRD2 PRL
14 adamantinous craniopharyngioma 10.0 DRD2 PRL
15 chronic eosinophilic pneumonia 10.0 COMT PRL
16 giant cell reparative granuloma 10.0 COMT NRG1
17 haverhill fever 10.0 COMT PRL
18 cerebritis 10.0
19 apperceptive agnosia 10.0 COMT DRD2
20 c8 deficiency, type ii 10.0 COMT DRD2
21 primary angle-closure glaucoma 10.0 COMT NRG1
22 colorectal adenocarcinoma 10.0 COMT DRD2
23 strongyloidiasis 10.0 COMT DRD2
24 urea cycle disorder 10.0 COMT DRD2
25 cytomegalic congenital adrenal hypoplasia 10.0 COMT DRD2
26 breast reconstruction 10.0 COMT DRD2
27 carotid stenosis 9.9 COMT DRD2
28 cecal benign neoplasm 9.9 COMT DRD2
29 cholesteatoma 9.9 COMT DRD2
30 hereditary multiple exostoses 9.9 COMT DRD2
31 necrobiosis lipoidica 9.9 COMT PRL
32 chondrodysplasia lethal recessive 9.9 COMT NRG1 PRL
33 hepatitis d 9.8 COMT DRD2 PRL
34 retinoblastoma 9.8 COMT DRD2 PRL
35 aortic valve disease 2 9.8 COMT DRD2
36 brain glioblastoma multiforme 9.8 COMT DRD2 NRG1
37 basal cell carcinoma 3 9.8 COMT DRD2
38 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 9.8 COMT PRL
39 bipolar disorder 9.7
40 borderline personality disorder 9.7
41 dementia 9.7
42 psychotic disorder 9.7
43 mood disorder 9.7
44 thyroiditis 9.7
45 delusional disorder 9.7
46 herpes simplex 9.7
47 encephalitis 9.7
48 oculo-auriculo-vertebral spectrum 9.7
49 dysphagia 9.7
50 neurosarcoidosis 9.7

Comorbidity relations with Schizophreniform Disorder via Phenotypic Disease Network (PDN): (show top 50) (show all 115)


Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Adjustment Disorder
Alcohol Abuse Alzheimer Disease
Amnestic Disorder Antisocial Personality Disorder
Anxiety Disorder Atypical Depressive Disorder
Bacteremia Bipolar Disorder
Blepharitis Borderline Personality Disorder
Brain Cancer Bronchitis
Bronchopneumonia Bullous Pemphigoid
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Kidney Failure
Chronic Myocardial Ischemia Chronic Ulcer of Skin
Communicating Hydrocephalus Conduct Disorder
Conjunctivitis Conversion Disorder
Cyclothymic Disorder Cystitis
Decubitus Ulcer Deficiency Anemia
Delusional Disorder Dependent Personality Disorder
Dermatomycosis Dysthymic Disorder
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Erythematosquamous Dermatosis Esophageal Disease
Esophagitis Familial Atrial Fibrillation
Fecal Incontinence Folic Acid Deficiency Anemia
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Hepatic Encephalopathy

Graphical network of the top 20 diseases related to Schizophreniform Disorder:



Diseases related to Schizophreniform Disorder

Symptoms & Phenotypes for Schizophreniform Disorder

UMLS symptoms related to Schizophreniform Disorder:


fatigue, sleep disturbances, photophobia, mental and behavioral signs and symptoms, personality changes, clouded consciousness, catatonic reaction, restlessness, pseudobulbar behavioral symptoms

Drugs & Therapeutics for Schizophreniform Disorder

Drugs for Schizophreniform Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Sulpiride Approved Phase 4 15676-16-1 5355
3
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
4
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
5
Armodafinil Approved, Investigational Phase 4 112111-43-0
6
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
7
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
8
Donepezil Approved Phase 4 120014-06-4 3152
9
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
10
Clozapine Approved Phase 4,Phase 1 5786-21-0 2818
11
Molindone Approved Phase 4 7416-34-4 23897
12
Pravastatin Approved Phase 4 81093-37-0 54687
13
Metformin Approved Phase 4 657-24-9 14219 4091
14
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
15
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
16
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
17
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
18
Citalopram Approved Phase 4 59729-33-8 2771
19
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
20 Antidepressive Agents Phase 4
21 Antidepressive Agents, Second-Generation Phase 4
22 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
24 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
28 sultopride Phase 4,Phase 2
29 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Cholinergic Agents Phase 4
31 Nicotinic Agonists Phase 4
32 Central Nervous System Stimulants Phase 4
33 Cytochrome P-450 CYP3A Inducers Phase 4
34
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
35 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1
37 Wakefulness-Promoting Agents Phase 4
38 Cholinesterase Inhibitors Phase 4
39 Nootropic Agents Phase 4,Phase 2
40 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
41 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Estrogens Phase 4,Phase 3,Phase 2
45 Anticholesteremic Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
47 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
48 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 120)
id Name Status NCT ID Phase
1 Association of Amisulpride Response in Schizophrenia With Brain Image Unknown status NCT02095938 Phase 4
2 Varenicline Adjunctive Treatment in Schizophrenia Unknown status NCT00492349 Phase 4
3 Antipsychotic Effects on Brain Function in Schizophrenia Unknown status NCT01913327 Phase 4
4 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4
5 The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder Completed NCT00044187 Phase 4
6 Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia Completed NCT02137993 Phase 4
7 Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS) Completed NCT00304655 Phase 4
8 Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia Completed NCT00485823 Phase 4
9 An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders Completed NCT01855074 Phase 4
10 Scale Validation Study for Prediction of Relapse and Short Term Rehospitalization in Patients With Schizophrenia Completed NCT00358852 Phase 4
11 Optimization of Treatment and Management of Schizophrenia in Europe Completed NCT01248195 Phase 4
12 A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis Completed NCT00246259 Phase 4
13 Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS) Completed NCT00053703 Phase 4
14 Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia Completed NCT00847600 Phase 4
15 Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia Completed NCT00103571 Phase 4
16 Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia Completed NCT00361543 Phase 4
17 Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia Completed NCT00595504 Phase 4
18 Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia Completed NCT01082588 Phase 4
19 Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia Completed NCT00337662 Phase 4
20 Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine Completed NCT00312598 Phase 4
21 Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia Completed NCT00330551 Phase 4
22 An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications. Completed NCT00391261 Phase 4
23 Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia Completed NCT00333177 Phase 4
24 Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis Completed NCT00320671 Phase 4
25 Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia Recruiting NCT03061136 Phase 4
26 Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men? Recruiting NCT01481883 Phase 4
27 Prednisolone Addition for Patients With Recent-onset Psychotic Disorder Recruiting NCT02949232 Phase 4
28 Integrated Care in Psychotic Disorders With Severe Mental Illness Recruiting NCT01888627 Phase 4
29 Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia Recruiting NCT01451736 Phase 4
30 DECIFER: Depression and Citalopram In First Episode Recovery Active, not recruiting NCT01041274 Phase 4
31 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Active, not recruiting NCT01339858 Phase 4
32 Schizophrenic Patients in Integrated Care Terminated NCT00681629 Phase 4
33 Optimizing Response in Psychosis Study Terminated NCT00314327 Phase 4
34 Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal Terminated NCT00314613 Phase 4
35 Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients Completed NCT00159770 Phase 3
36 Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study Completed NCT00145444 Phase 3
37 CAFE Comparison of Atypicals in First Episode of Psychosis Completed NCT00034892 Phase 3
38 Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants Completed NCT00419146 Phase 2, Phase 3
39 Open-label Ziprasidone Study for Psychosis Treatment in Adolescents Completed NCT00421954 Phase 3
40 A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis Completed NCT00216580 Phase 3
41 A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform Recruiting NCT02431702 Phase 3
42 Simvastatin Addition for Patients With Recent-onset Schizophrenia Recruiting NCT01999309 Phase 3
43 Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia Recruiting NCT01121042 Phase 3
44 Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder Recruiting NCT03043820 Phase 3
45 The Topical Niacin Skin Flush Test in First Episode Psychosis Terminated NCT01324297 Phase 3
46 Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis Unknown status NCT00465920 Phase 2
47 A Definitive Estrogen Patch Study (ADEPT) Completed NCT00357006 Phase 2
48 Effectiveness of Adherence Therapy for Schizophrenia Completed NCT01780116 Phase 1, Phase 2
49 Clinical Estradiol Trial in Women With Schizophrenia Completed NCT00206570 Phase 2
50 The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study Completed NCT00206557 Phase 2

Search NIH Clinical Center for Schizophreniform Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: psychotic disorders

Genetic Tests for Schizophreniform Disorder

Anatomical Context for Schizophreniform Disorder

MalaCards organs/tissues related to Schizophreniform Disorder:

39
Brain, Thyroid, Spinal Cord

Publications for Schizophreniform Disorder

Articles related to Schizophreniform Disorder:

(show top 50) (show all 89)
id Title Authors Year
1
Hypocalcemia Masquerading as Schizophreniform Disorder. ( 27833232 )
2016
2
White matter alterations associated with suicide in patients with schizophrenia or schizophreniform disorder. ( 26774424 )
2016
3
Similarities in early course among men and women with a first episode of schizophrenia and schizophreniform disorder. ( 21614663 )
2012
4
Treatment of schizophreniform disorder by aripiprazole in a female adolescent with 22q11.2 deletion syndrome. ( 20493229 )
2010
5
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). ( 19369319 )
2009
6
Hypothermia and rhabdomyolysis following olanzapine injection in an adolescent with schizophreniform disorder. ( 19555799 )
2009
7
Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. ( 19154213 )
2009
8
Specific brain structural abnormalities in first-episode schizophrenia. A comparative study with patients with schizophreniform disorder, non-schizophrenic non-affective psychoses and healthy volunteers. ( 19796919 )
2009
9
Effects of a neuregulin 1 variant on conversion to schizophrenia and schizophreniform disorder in people at high risk for psychosis. ( 19156152 )
2009
10
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). ( 19819114 )
2009
11
Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response. ( 18280582 )
2008
12
Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder. ( 18053652 )
2008
13
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. ( 18312044 )
2008
14
Schizophreniform disorder after heat injury in a military recruit. ( 18621941 )
2008
15
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. ( 18374841 )
2008
16
Predictors of the evolution towards schizophrenia or mood disorder in patients with schizophreniform disorder. ( 17851043 )
2007
17
Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. ( 17854239 )
2007
18
Chromosomal translocation t(1;4) (p21;p14) indicating possible susceptibility loci for schizophreniform disorder and mental retardation. ( 17827423 )
2007
19
Supportive psychotherapy for a patient with psychosis: schizophreniform disorder. ( 21103151 )
2006
20
Improvement of psychiatric symptoms after electroconvulsive therapy in young adults with intractable first-episode schizophrenia and schizophreniform disorder. ( 17077598 )
2006
21
Neuropsychological performance at the age of 13 years and adult schizophreniform disorder: prospective birth cohort study. ( 17077440 )
2006
22
Early insight predicts depression and attempted suicide after 4 years in first-episode schizophrenia and schizophreniform disorder. ( 16279874 )
2005
23
Patients with schizophreniform disorder use verbal descriptions for the representation of visual categories. ( 14982130 )
2004
24
Cotard's syndrome with schizophreniform disorder can be successfully treated with electroconvulsive therapy: case report. ( 15069468 )
2004
25
A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder. ( 15206670 )
2004
26
Childhood origins of violent behaviour in adults with schizophreniform disorder. ( 14645023 )
2003
27
Schizophreniform disorder with cerebrospinal fluid PCR positivity for herpes simplex virus type 1. ( 14530627 )
2003
28
Exploration of dimensions of psychopathology in neuroleptic-naA^ve patients with recent-onset schizophrenia/schizophreniform disorder. ( 14572620 )
2003
29
Distinguishing between first-admission schizophreniform disorder and schizophrenia. ( 12765743 )
2003
30
Outcome of schizophreniform disorder. ( 12773271 )
2003
31
Persistent early childhood developmental impairment may be associated with later schizophreniform disorder. ( 12588823 )
2003
32
A follow-up study of patients with DSM-IV schizophreniform disorder. ( 11873709 )
2002
33
Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. ( 11982449 )
2002
34
Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. ( 11074871 )
2000
35
First-episode schizophreniform disorder: comparisons with first-episode schizophrenia. ( 11099883 )
2000
36
Treatment of a biracial child with schizophreniform disorder: cultural formulation. ( 10975171 )
2000
37
Schizophreniform disorder: exception proves the rule. ( 10360149 )
1999
38
Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. ( 10584762 )
1999
39
Induction of a schizophreniform disorder by a spinal cord stimulator. ( 9989125 )
1999
40
Family history of DSM-III-R schizophreniform disorder with good prognostic features. ( 9653543 )
1998
41
DSM-III-R schizophreniform disorder with good prognostic features: a six-year follow-up. ( 9533972 )
1998
42
Comorbidity of schizophreniform disorder and borderline personality disorder in an 18-year-old black woman. ( 9521370 )
1998
43
Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: baseline rate in a group of patients from an Irish catchment area. ( 9734543 )
1998
44
Oculo-auriculo-vertebral spectrum disorder (Goldenhar "syndrome") coexisting with schizophreniform disorder. ( 9667580 )
1998
45
The effect of apolipoprotein E genotype on expression of an autosomal dominant schizophreniform disorder with progressive dementia and neurofibrillary tangles. ( 9018389 )
1997
46
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. ( 9090331 )
1997
47
Neurobiological findings in first admission patients with schizophrenia or schizophreniform disorder. ( 9151009 )
1997
48
Platelet [3H]dopamine uptake is differentially affected by neuroleptic drug treatment in schizophrenia and schizophreniform disorder. ( 8861176 )
1996
49
Schizophreniform disorder: a 1-year follow-up study. ( 8861514 )
1996
50
Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder. ( 9029665 )
1996

Variations for Schizophreniform Disorder

Expression for Schizophreniform Disorder

Search GEO for disease gene expression data for Schizophreniform Disorder.

Pathways for Schizophreniform Disorder

Pathways related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
10.66 NRG1 PRL

GO Terms for Schizophreniform Disorder

Cellular components related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 dendritic spine GO:0043197 9.26 COMT DRD2
2 cell body GO:0044297 9.16 COMT NRG1
3 dendrite GO:0030425 9.13 COMT DRD2 NRG1
4 axon GO:0030424 8.8 COMT DRD2 NRG1

Biological processes related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.4 DRD2 PRL
2 female pregnancy GO:0007565 9.37 COMT PRL
3 locomotory behavior GO:0007626 9.32 DRD2 NRG1
4 synapse assembly GO:0007416 9.26 DRD2 NRG1
5 startle response GO:0001964 9.16 DRD2 NRG1
6 dopamine metabolic process GO:0042417 8.96 COMT DRD2
7 response to drug GO:0042493 8.92 COMT DRD2 PRL SEMA3C

Sources for Schizophreniform Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....